Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis

All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first measure the effects of CP-690,550 on cholesterol levels and then the effects of adding atorvastatin on those levels.

Inclusion Criteria:

• must be diagnosed as having active rheumatoid arthritis
• agree to participate in the study and sign and informed consent document

Exclusion Criteria:

• History of serious infection within the past 6 months
• test positive for TB
• have any uncontrolled clinically significant disease or laboratory tests
• require administration of prohibited medications during the study